- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02397564
Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG (Er:YAG)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Scars are a common complaint of patients at presentation to a dermatology office. To optimize cosmetic results, the investigators propose to compare erbium-doped yttrium aluminium garnet (Er:YAG) laser therapy on two different settings: traditional ablative versus fractional ablative. A side to side comparison of split scars will be done to evaluate the two settings. Fractionated photothermolysis (fractional setting) has improved the field of laser surgery by allowing the surgery to target microscopic treatment zones (MTZ). MTZ's allow for cylinders of damage created by laser surgery to be surrounded by normal, unaffected skin. This acts as a reservoir for healing and allows for the microwounds created by laser treatment to heal quickly and with minimal discomfort.
Objective: To compare efficacy and cosmetic appearance of scars treated with Er:YAG ablative laser on traditional ablative resurfacing setting versus fractional ablative resurfacing setting.
Methods: Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment. Pictures of the scar will be taken at a 45 degree and 90 degree angle at baseline, before each treatment, after each treatment, and at all follow up appointments. The patients will be blinded as to which side is treated with which laser setting. At the end of the trial, they will be offered the chance to have the side they felt had less improvement treated with the laser device that had been used on the contralateral side of the scar.
Results: A panel of three blinded dermatologists will evaluate the scar on a well-established five point grading scale for erythema, height and texture, and overall cosmetic outcome. The mean, standard deviation, and kappa values will be calculated. Patients will be asked the same scar evaluation questions as the panel as well as their overall satisfaction, how much pain was associated with the procedure, which laser they preferred, and would they recommend treatment to a friend or family member.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- over 8 weeks s/p scar
- linear closure
- visibly symmetric scar
- over 18 years old
Exclusion Criteria:
- concomitant treatment of involved skin
- propensity for keloid scarring
- use of oral retinoids for the past 1 year
- pregnancy
- immunosuppression
- prior laser to the area
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Enroll 20 patients for nonsurgical treatment of surgical scars.
Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting.
The patients will receive 3 treatments at monthly intervals.
They will follow up at 1 and 2 months after the treatment.
|
Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Observer Scar Assessment Scale (POSAS)
Time Frame: 5 months
|
It uses a 10-point scoring system with a score of 1 representing a normal-appearing skin and a score of 10 representing the worst possible scar.
Total scores range from 6 to 60 with the lower score indicate a better outcome.
|
5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Preference
Time Frame: 5 months
|
The number of patients who preferred the fractionated laser
|
5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Timothy S Brown, MD, University of Louisville
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14.1075
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-Surgical Scars
-
Catalysis SLCompleted
-
Henry Ford Health SystemAmerican Academy of Cosmetic SurgeryCompletedPost Surgical ScarsUnited States
-
Catalysis SLCompleted
-
Cynosure, Inc.Terminated
-
University Hospital, GhentCompleted
-
University Hospital, GhentCompletedScars After Surgical InterventionBelgium
-
University of British ColumbiaUnknown
-
Merz Pharmaceuticals GmbHCompletedPost Dermatological Surgery ScarsGermany
-
IHU StrasbourgRhythm Diagnostic SystemsCompletedVisceral and Digestive Surgery | Post-surgical Monitoring | Post-surgical RehabilitationFrance
-
Sheikh Zayed Medical CollegeNot yet recruitingPost-Surgical Complication
Clinical Trials on Er:YAG laser, traditional and fractional settings
-
Laserklinik KarlsruheCompleted
-
Pantec Biosolutions AGMedical University of ViennaCompletedInfluenza in HumanAustria
-
Second Affiliated Hospital, School of Medicine,...CompletedAcne | Atrophic ScarChina
-
Dong-A UniversityCompletedBowen's DiseaseKorea, Republic of
-
Dong-A UniversityCompletedActinic CheilitisKorea, Republic of
-
Netherlands Institute for Pigment DisordersAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Completed
-
Tufts University School of Dental MedicineUnknownChronic PeriodontitisUnited States
-
Hallym University Kangnam Sacred Heart HospitalRecruitingIntense Pulsed Light | Erbium-yttrium Aluminum Garnet Laser | Scar PreventionKorea, Republic of
-
Brasilia University HospitalUnknown
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions